Brain arteriovenous malformations (bAVM) are tangles of abnormal, dilated vessels that directly shunt blood between the arteries and veins. The pathogenesis of bAVM is currently unknown. Patients with hereditary hemorrhagic telangiectasia (HHT) have a higher prevalence of bAVM than the general population. Animal models are important tools for dissecting the disease etiopathogenesis and for testing new therapies. Here, we introduce a method that induces the bAVM phenotype through regional deletion of activin-like kinase 1 ( Alk1 , the causal gene for HHT2) and vascular endothelial growth factor (VEGF) stimulation.
Introduction
Arteriovenous malformations (AVM) are tangles of abnormal, dilated vessels that directly shunt blood between the arteries and veins without a true capillary bed. It is a common phenotype in patients with hereditary hemorrhagic telangiectasia (HHT). The two main subtypes of HHT are as follows: (a) HHT1, caused by loss-of-function mutations in the endoglin ( ENG ), a type III transforming growth factor-beta (TGFβ) coreceptor, and (b) HHT2, caused by mutations in activin-like kinase 1 ( ALK1 or ACVRL1 ) gene, a type I TGFβ signaling receptor. Compared to the general population, the prevalence of bAVM in HHT1 ( ENG ) is 1,000-fold higher, and in HHT2 ( ALK1 ), 100-fold higher (10/100,000) [ 1 ] .
Brain AVM accounts for 1-2 % of all strokes [ 2 ] . The malformed vessels are fragile and prone to rupture, and rupture of bAVM can lead to intracranial hemorrhage and serious neurological disability or death. The risk of intracranial hemorrhage of bAVM is about 2-4 % per year [ 2 ] . Patients with unruptured bAVM can develop many neurological symptoms, e.g., seizures and headache. The pathogenesis of bAVM is currently unknown [ 3 ] .
To better understand the underlying mechanisms of bAVM formation, it is critical to establish reproducible and reliable animal models that mimic both macroscopic and microscopic morphological features of the human bAVM lesional phenotype, including large dysplastic, tangled vessels, and arteriovenous shunting.
Previous studies have shown that homozygous deletion of Alk1 or endoglin results in embryonic lethality [ 4 , 5 ] . Interestingly, induction of Alk1 gene deletion at the adult stage leads to AVM formation only in small intestinal, pulmonary, and uterine vessels, but not in the brain [ 6 ] . Our group has previously shown that vascular endothelial growth factor (VEGF) stimulation in adult Alk1 or Eng heterozygous mice results in vascular abnormalities at the capillary level [ 7 -9 ] , which supports the response-to-injury paradigm. Thus, other than genetic modifi cation, environmental stimulus might also be involved in the onset of bAVM formation in adults. We have successfully induced the AVM phenotype in the adult mouse brain through regional Alk1 deletion in combination with VEGF stimulation [ 10 ] .
Materials
Adult Alk1 2f/2f mice (exons 4-6 fl anked by loxP sites) [ 11 ] .
Adenoviral vector with cytomegalovirus (CMV) promoter
driving Cre recombinase expression (Ad-Cre, Vector Biolabs, Philadelphia, PA, USA).
2. Control adenoviral vector with green fl uorescent protein expression (Ad-GFP, Vector Biolabs).
3. Adeno-associated viral vectors expressing vascular endothelial growth factor (AAV-VEGF) packaged in AAV serotype 1 capsid [ 12 -14 ] .
Adeno-associated viral vectors expressing β-galactosidase
(AAV-LacZ) [ 12 -14 ] . 2. Leica CM1900 cryostat.
3. Fluorescent microscope.
Methods
1. This protocol was approved by the Animal Care Committee of the University of California, San Francisco.
2. Following induction of anesthesia with 5 % isofl urane, 8-weekold Alk1 2f/2f mice were placed in a stereotactic frame (David Kopf Instruments) with a mouth holder. The anesthesia was maintained with 1.5 % isofl urane.
3. A 1-cm midline skin incision at the top of the head was made to expose the sagittal suture and bregma.
4.
A burr hole was drilled in the pericranium 2 mm lateral to the sagittal suture and 1 mm posterior to the coronal suture.
A 10-μL
Hamilton syringe was slowly inserted into the left caudate nucleus at a depth of 3.0 mm under the dura ( see Note 2 ).
6. A 2-μL viral suspension containing 2 × 10 7 plaque forming unit (PFU) Ad-Cre and 1 μL containing 2 × 10 9 genome copies (gcs) of AAV-VEGF were injected into the right basal ganglia at a rate of 0.2 μL/min using a ultramicro pump (World Precision Instruments). For the control group, Ad-GFP and AAV-LacZ were used.
7. The needle was retained in the brain for 10 min and then slowly withdrawn over a 5-min period ( see Note 3 ).
Assorted Surgical Instruments

Latex Vessel Casting
Determining Dysplasia Index
Stereotactic Injection of Viral Vectors into the Basal Ganglia ( See Note 1 )
8. The skin wound was closed with a 4-0 suture. 9. Brain sections were collected for analysis 8 weeks later ( see Note 4 ).
Visualizing malformed vessels in the brain is the fi rst step to confi rm the successful induction of the AVM phenotype. There are different techniques to visualize cerebral vasculature in small animals, including casting vessels with microfi l [ 10 , 15 ] or latex. Latex perfusion is the usual choice to display the AVM-like phenotype, since the particles in the latex dye are too big to pass through the capillaries [ 6 ] . Latex will present in the veins after intra-artery infusion when there is direct fl ow between arteries and veins (i.e., AV shunting, a major characteristic of AVM). Latex perfusion was fi rst described by Coyle and Jokelainen [ 16 ] and later modifi ed by Maeda et al. [ 17 ] . It is the liquid rubber that solidifi es after the vasculature is fi lled. Lesion volume measurement and dysplastic vessel index quantifi cation (the number of vessels larger than 15 μm/200 vessels) [ 8 -10 , 18 -20 ] are methods to evaluate the severity of the phenotype, enabling quantitative measurement of cerebrovascular abnormality, which could provide critical outcome evaluation in innovative brain vascular malformation therapies.
1. Deep-anesthetize the mice with isofl urane. Open the abdominal and thoracic cavities and expose the heart.
2. Cut both the left and right atria. Slowly inject 1-mL blue latex dye into the left ventricle with a 25-gauge 5-mL syringe ( see Note 5 ).
3. Remove the brain and fi x with 4 % paraformaldehyde overnight.
4. Dehydrate the brain tissue using methanol series (50, 75, 95, and 100 % methanol, 24 h for each concentration).
5.
Clarify the brain with benzyl alcohol/benzyl benzoate (1:1 ratio).
6. Cut the brain coronally using a razor blade. Image the brain AVM vessels under the microscope (Fig. 1 ).
1. After imaging the latex-perfused brain slide, rehydrate the brain tissue and snap-freeze in dry ice.
2. Coronally section the brain serially into 50-μm-thick sections using a cryostat. Section the entire brain region containing the AVM lesion.
3. Under a 5× microscope objective lens, image both the AVM lesion side and the contralateral corresponding region.
4. Quantify the latex area using NIH Image 1.63 software after binary (Fig. 2 ) .
Analysis
Vessel Casting with Latex Perfusion
Lesion Volume Quantifi cation
5. Based on known section thickness, estimate the volume by summing serial volumes. This method is adapted from what we have used for quantifying infarct volume in mice with middle cerebral artery occlusion (MCAO) [ 21 ] .
1. 8 weeks following viral injection, perfuse the mice with cold 1× PBS through the left ventricle of the heart, using a Masterfl ex Pump Controller (Cole Parmer Instrument, Vernon Hills, IL, USA) at 4 mL/min.
2.
Harvest the brains and snap-freeze in dry ice.
3. Coronally slice the brain serially at 20-μm thickness using a cryostat.
4. Choose two sections per mouse, one mm rostral and one mm caudal of the injection site, for vessel staining using fl uoresceinlycopersicon esculentum-lectin (1:200, Vector Laboratory) ( Fig. 3 ; see Note 7 ). 
Capillary Density and Dysplasia Index Quantifi cation ( See Note 6 )
Notes
1. The vectors can also be injected into other brain regions, such as the cortex, to induce the AVM phenotype.
2. During viral injection, fi x the mouse head in a horizontal position, and insert the needle perpendicularly into the surface of the dura. Needle insertion at an angle will affect the lesion location or may even inject into the brain ventricle.
3. After viral injection, it is critical to retain the needle in the brain for 10 min and then slowly withdraw the needle. Pulling the needle out too fast could lead to the virus leaking out.
4.
Other than Ad-Cre-mediated regional gene deletion, Alk1 can be conditionally deleted in adult mice, either systemically or tissue-/cell-specifi cally by crossbreeding Alk1 2f/2f mice with transgenic mouse lines that express inducible Cre recombinase. The brain AVM phenotype can be induced in mice that have systemic/endothelial-specifi c Alk1 gene deletion through intra-brain injection of AAV-VEGF.
Fig. 3
Representative image of a brain section with lectin staining. Alk1 2f/2f mouse received 2 × 10 7 PFU Ad-Cre and 2 × 10 9 gcs of AAV-VEGF in the basal ganglia for 8 weeks. A cluster of dysplastic vessels formed in the viral injection site ( white arrows ). Scale bar: 100 μm 5. For latex perfusion, make sure that the latex is fresh and that no solidifi ed clusters have formed.
6. Vessels can also be visualized by perfusing fl uorescent-labeled lectin through intravenous injection.
7. The sections can be stained with endothelial-specifi c antibodies, such as the anti-CD31 antibody.
